NCT03114319 2026-04-16
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Terminated
Clinical Trials
10,790 trialsNCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT05012124 2026-04-16
Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE
University of Washington
Phase NA Terminated
NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT02095184 2026-04-15
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
Phase NA Terminated
NCT03520686 2026-04-15
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT05397093 2026-04-15
ITIL-306 in Advanced Solid Tumors
Instil Bio
Phase 1 Terminated
NCT01507506 2026-04-14
SPECTRO GLIO
Institut Claudius Regaud
Phase 3 Terminated
NCT01580618 2026-04-14
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
Kaiser Permanente
Phase 2/3 Terminated
NCT01642017 2026-04-14
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT03016156 2026-04-14
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
St. Jude Children's Research Hospital
Phase NA Terminated
NCT03786081 2026-04-14
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
Phase 1/2 Terminated
NCT03846128 2026-04-14
BIOSUNTOX
University Hospital, Rouen
Terminated
NCT04600466 2026-04-14
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
The University of Texas Health Science Center at San Antonio
Terminated
NCT05189366 2026-04-14
SOPHNEURO
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT06088654 2026-04-14
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Innate Pharma
Phase 1/2 Terminated
NCT06685068 2026-04-14
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT00802711 2026-04-13
3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer
Cancer Trials Ireland
Phase NA Terminated
NCT01081028 2026-04-13
Connect® MM- The Multiple Myeloma Disease Registry
Celgene
Terminated
NCT01164150 2026-04-13
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Cancer Trials Ireland
Phase 2 Terminated
NCT02151019 2026-04-13
TRI-LARC
Cancer Trials Ireland
Phase 1/2 Terminated
NCT02764086 2026-04-13
INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer
Cancer Trials Ireland
Phase 1/2 Terminated
NCT03621124 2026-04-13
Maladaptive Adipose Tissue Activity in Cancer
Virginia Commonwealth University
Terminated
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT04924192 2026-04-13
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT05088876 2026-04-13
ParOP
Insel Gruppe AG, University Hospital Bern
Phase 4 Terminated
NCT05180474 2026-04-13
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
Phase 1/2 Terminated
NCT05518110 2026-04-13
PaTcH
Cancer Trials Ireland
Phase 2 Terminated
NCT05639153 2026-04-13
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
Zhejiang Doer Biologics Co., Ltd.
Phase 1 Terminated
NCT05879185 2026-04-13
A Study of XmAb23104 in People With Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT05879627 2026-04-13
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Terminated
NCT02819752 2026-04-09
PEACH
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT04853329 2026-04-09
Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
Conjupro Biotherapeutics, Inc.
Phase 1 Terminated
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT06021600 2026-04-09
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07000344 2026-04-09
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
Peking Union Medical College Hospital
Phase NA Terminated
NCT07479381 2026-04-09
CLEAR
Harbinger Health
Terminated
NCT03699995 2026-04-08
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
OHSU Knight Cancer Institute
Phase NA Terminated
NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
NCT05262530 2026-04-08
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT06034197 2026-04-08
Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy
Stanford University
Phase EARLY_PHASE1 Terminated
NCT02668770 2026-04-07
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05853458 2026-04-07
HU-F-AIM
Novartis
Phase 4 Terminated
NCT07035067 2026-04-07
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
PeriPharm
Terminated
NCT02679963 2026-04-06
PIPSeN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated